Publications in collaboration with researchers from Instituto de Investigación Sanitaria Gregorio Marañón (52)

2024

  1. Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease

    Revista Espanola de Enfermedades Digestivas, Vol. 116, Núm. 9, pp. 478-483

  2. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  3. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease

    Biomedicine and Pharmacotherapy, Vol. 159

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  4. Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress

    Scientific Reports, Vol. 12, Núm. 1

  5. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

    Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83

2021

  1. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 198

  2. Conocimientos, percepciones, actitud, barreras y facilitadores del uso de biosimilares entre médicos y farmacéuticos de hospital: Una encuesta española

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 5, pp. 240-246

  3. Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658](S0210570520301606)(10.1016/j.gastrohep.2020.04.004)

    Gastroenterologia y Hepatologia

  4. Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing

    European journal of gastroenterology & hepatology, Vol. 33, Núm. 1S Suppl 1, pp. e796-e802

2020

  1. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 7, pp. 408-413

  2. Differential expression of SMAD genes and S1PR1 on circulating cd4+ t cells in multiple sclerosis and crohn’s disease

    International Journal of Molecular Sciences, Vol. 21, Núm. 2

  3. History of inflammatory bowel disease on eleven infographics

    Gastroenterologia y Hepatologia

  4. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study

    BMJ Open Gastroenterology, Vol. 7, Núm. 1

  5. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 10, pp. 649-658

  6. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 2, pp. 97-105